“…In surfactant replacement therapy, Knowledge to it's molecular constructure and biochemistry activity study, surfactant can separate into four protein of SP-A,B, C and D, and the replacement treatment has used two SP-B and SP-C from them to treat NRDS, this choice for surfactant replacement is in the goal to get more effective clinical result [2,3]. For glucocorticoid therapy, it reported glucocorticoid gene related with lung development and it presents that woman received betamethasone can accelerate fetal lung maturity, at later time, glucocorticoid to neonatal direct therapy after delivery also can see primary outcome to enhance pulmonary maturity [4,5].…”